荃信生物：QX027N注射液两项适应症获临床试验许可

财中社07-31

7月31日，荃信生物（02509）发布公告，近日，公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可，分别拟用于治疗慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉。　　这次获批是QX027N继特应性皮炎及哮喘后新增的两项呼吸系统相关适应症。公司将加快该候选药物的临床开发节奏，以巩固在相关领域的领先优势。　　此外，公司与LE2025 Therapeutics AG...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2655636655?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-31 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655636655","market":"hk","top_or_hot":-1,"title":"荃信生物：QX027N注射液两项适应症获临床试验许可","media":"财中社","content":"<div>\n<p>7月31日，荃信生物（02509）发布公告，近日，公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可，分别拟用于治疗慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉。　　这次获批是QX027N继特应性皮炎及哮喘后新增的两项呼吸系统相关适应症。公司将加快该候选药物的临床开发节奏，以巩固在相关领域的领先优势。　　此外，公司与LE2025 Therapeutics AG...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607313828550155.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荃信生物：QX027N注射液两项适应症获临床试验许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荃信生物：QX027N注射液两项适应症获临床试验许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-31 20:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202607313828550155.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月31日，荃信生物（02509）发布公告，近日，公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可，分别拟用于治疗慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉。　　这次获批是QX027N继特应性皮炎及哮喘后新增的两项呼吸系统相关适应症。公司将加快该候选药物的临床开发节奏，以巩固在相关领域的领先优势。　　此外，公司与LE2025 Therapeutics AG...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607313828550155.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607313828550155.html","article_id":"2655636655","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828550155.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655636655","pubTimestamp":1785499260,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"7月31日，荃信生物（02509）发布公告，近日，公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可，分别拟用于治疗慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉。这次获批是QX027N继特应性皮炎及哮喘后新增的两项呼吸系统相关适应症。公司将加快该候选药物的临床开发节奏，以巩固在相关领域的领先优势。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BMED":"iShares Health Innovation Active ETF","PSYK":"PSYK ETF","02509":"荃信生物-B","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","MDTX":"Corgi MediaTek 2x Daily ETF"},"translate_title":"Tsuen Xin Bio: Two indications of QX027N injection obtained clinical trial approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDTX":1.5,"02509":1.5,"PSYK":1.5,"IBBQ":1.5,"IBBJ":1.5,"BMED":1.5},"content_text":"7月31日，荃信生物（02509）发布公告，近日，公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可，分别拟用于治疗慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉。　　这次获批是QX027N继特应性皮炎及哮喘后新增的两项呼吸系统相关适应症。公司将加快该候选药物的临床开发节奏，以巩固在相关领域的领先优势。　　此外，公司与LE2025 Therapeutics AG（Windward Bio的附属公司）签订许可及合作协议，授予LE2025在全球范围内（中国内地、台湾、香港及澳门除外）开发及商业化QX027N的独家权利。作为回报，公司将有权获得总额最高7亿美元的款项，包括首付款、Windward Bio的股权、开发及商业里程碑付款，以及QX027N在上述授权区域净销售额对应的分级特许权使用费。截至公告日期，公司已收到相关首付款及Windward Bio对应股权。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655636655","isCrawlerRequest":true}